Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →
Vaderis Therapeutics closes $152 million Series B financing to support its global Phase 3 HEROIC study for engasertib in hereditary hemorrhagic telangiectasia.
Vaderis Therapeutics has secured $152 million in an oversubscribed Series B financing. This funding will facilitate the initiation of the HEROIC Phase 3 clinical study for engasertib targeting hereditary hemorrhagic telangiectasia. The financing involved both new and existing investors, highlighting confidence in the drug's potential. Proceeds are expected to support operations through regulatory submissions and potential U.S
Company Information
Company
Vaderis Therapeutics
About
Vaderis Therapeutics is a clinical-stage biopharmaceutical company focused on developing targeted therapies for rare vascular diseases. They are specifically working on engasertib, an investigational oral allosteric AKT inhibitor, aimed at treating hereditary hemorrhagic telangiectasia (HHT), a rare genetic disorder with no approved treatments. The company's efforts are centered around addressing significant unmet medical needs in this patient population.
Predictive Intelligence
Strategic
ML-powered predictions for Vaderis Therapeutics's next move
